A pooled analysis of four clinical trials of delandistrogene moxeparvovec in predominantly young, ambulatory patients with Duchenne muscular dystrophy reported a manageable cardiac safety profile over up to five years of follow-up. The dataset supports continued confidence in longer-term monitoring expectations for gene therapy recipients, where cardiac outcomes are a central concern in DMD. While efficacy endpoints are not detailed in the provided brief, the emphasis on cardiac safety duration reinforces how sponsors are validating systemic risks beyond early post-infusion periods.